best peptides FAQ

Switch to intravitreal injection or develop a lipophilic prodrug conjugate. The blood-retinal barrier excludes hydrophilic molecules above 500 Da. Neurotrophic peptides are 10–30× larger. Systemic NGF administered subcutaneously in rats showed undetectable retinal levels 6 hours post-injection measured by ELISA. Cell-penetrating peptide conjugates (TAT-BDNF) or nanoparticle encapsulation improves penetration but adds synthesis complexity most academic labs can't handle in-house.

No meaningful protection. Oral glutathione has an absolute bioavailability below 5% due to degradation by intestinal peptidases and hepatic first-pass metabolism. The small fraction that survives digestion is broken into constituent amino acids (glutamate, cysteine, glycine) before reaching systemic circulation. These amino acids can be reassembled into glutathione intracellularly, but the process is too slow to counteract the rapid ROS generation alcohol triggers. Clinical trials using oral glutathione for oxidative stress conditions routinely show no change in plasma glutathione levels even at gram-scale doses.

Dose 2–5 milligrams subcutaneously 2–3 times per week for 4 weeks, targeting systemic inflammation rather than localized injection. TB-500's longer half-life (10 days) allows broader anti-inflammatory coverage across multiple tendon sites simultaneously. Useful when pain migrates between flexor tendons. Pair with eccentric wrist curls and finger extensor training to rebalance flexor-extensor strength ratios. Expect measurable pain reduction within 14–21 days, but tendinitis resolution requires addressing the training volume or technique error causing chronic strain.

BPC-157 is the most studied peptide for tendon-to-bone injuries, which is exactly what chronic rotator cuff tendinopathy represents. Research shows it works by promoting fibroblast migration and increasing Type I collagen deposition at the injury site. The structural protein that gives tendons their tensile strength. If you've rested for six weeks and pain returns on your first paddle session, the underlying issue is likely incomplete healing at the cellular level. BPC-157 accelerates that repair phase by improving blood flow and recruiting the cells needed to rebuild the extracellular matrix.

Combine BPC-157 with TB-500 for 8–12 weeks. Chronic lesions involve established fibrosis and persistent low-grade inflammation. BPC-157 alone may not suppress the cytokine cascade maintaining the lesion. TB-500's IL-6 downregulation addresses the inflammatory maintenance signal, while BPC-157 remodels existing scar tissue. Research in chronic tendinopathy (structurally analogous to vocal nodules) showed combination therapy reduced lesion size by 35–50% over 10 weeks where monotherapy showed 15–20% reduction.

Palpable firmness three weeks post-op indicates early fibrosis. Excessive collagen deposition overwhelming the remodeling process. Increase GHK-Cu frequency to five times weekly to enhance MMP-9 activity, which breaks down immature collagen bundles before they organize into permanent scar tissue. Combining with manual lymphatic drainage accelerates interstitial fluid clearance, reducing the inflammatory signals that drive fibroblast activation. If lumps persist beyond week 8, peptides alone are insufficient. Ultrasound-guided triamcinolone injection directly into fibrotic areas breaks down established scar tissue more effectively.

Start with KPV at 500 mcg orally twice daily. Persistent bloating after antibiotics is typically driven by ongoing low-grade inflammation and histamine release from dysregulated mast cells. KPV addresses both by blocking NF-κB and stabilizing mast cell degranulation. Pair this with a low-FODMAP diet for 10–14 days to reduce fermentable substrate load while the gut barrier repairs. If bloating persists beyond two weeks on KPV, consider adding BPC-157 (250 mcg subcutaneously daily) to address potential barrier permeability that's allowing bacterial metabolites to trigger immune responses.

Start peptide application within 24–48 hours post-surgery, once initial hemostasis is achieved. The acute inflammatory phase is when VEGF signaling and fibroblast migration are most responsive to peptide intervention. Research protocols typically use twice-daily topical application or a single subgingival injection at the surgical site immediately after closure. The peptide doesn't interfere with sutures or wound closure. It accelerates the re-epithelialization phase that follows. A study in the International Journal of Periodontics and Restorative Dentistry found that patients using BPC-157 gel post-operatively reported 40% less pain at day three and complete epithelial coverage 4.2 days earlier than controls.

Mild soreness lasting 12–24 hours is common with subcutaneous BPC-157 administration and typically indicates proper injection technique (shallow angle, slower injection rate). Persistent soreness beyond 48 hours or accompanied by redness, heat, or swelling suggests either contamination or an inflammatory response to the carrier solution (often bacteriostatic water). Rotate injection sites (abdomen, thighs, upper glutes) to prevent localized tissue saturation. If soreness persists across multiple sites, consider switching to a different bacteriostatic water source. Some athletes react to benzyl alcohol concentrations above 0.9%. Intramuscular BPC-157 creates more post-injection discomfort than subcutaneous due to higher tissue density; unless treating a specific localized injury, subcutaneous administration provides equivalent systemic benefit with less discomfort.

NSAIDs don't block peptide mechanisms directly, but they suppress COX-2 (cyclooxygenase-2), an enzyme required for the early inflammatory phase that signals tissue repair. Using NSAIDs during the first 72 hours post-injury or during peptide loading phases may delay healing by 20–40%. Corticosteroid injections are worse. They directly inhibit fibroblast proliferation and collagen synthesis, the exact processes BPC-157 and TB-500 promote. If you've had a cortisone injection, wait four weeks before starting peptide therapy to allow steroid suppression to clear.

Cisplatin and carboplatin cause irreversible hearing loss in 40–80% of patients through cochlear hair cell apoptosis. P21 and similar antioxidant peptides have shown protective effects in animal models when administered concurrently with chemotherapy. Discussing this with your oncologist is essential. Some peptides theoretically interfere with chemotherapy efficacy by reducing oxidative stress in tumor cells as well. Timing and dosing must be coordinated to target cochlear protection without compromising cancer treatment.

Subcutaneous peptide injections can cause temporary erythema (redness) or mild induration (firmness) at the injection site. This resolves within 12–24 hours in most cases and indicates localised histamine release, not infection. If redness persists beyond 48 hours, spreads, or is accompanied by warmth and pain, bacterial contamination is possible. Stop injections and consult a medical professional. The most common cause of persistent irritation is injecting peptides that were improperly reconstituted (too-fast injection of bacteriostatic water causing aggregation) or stored above 8°C, which denatures proteins into immunogenic fragments.

If lyophilised (unreconstituted) peptides were exposed to ambient temperature (20–25°C) for 48–72 hours during shipping, they typically retain 85–95% potency. Peptides in powder form are more stable than reconstituted solutions. However, exposure above 30°C for extended periods (e.g., sitting in a hot mailbox for 8+ hours) can cause irreversible degradation. Upon arrival, check for discolouration or clumping in the powder. Pure lyophilised peptides should appear as a fine white or off-white powder. If the powder looks yellow, brown, or crystallised, degradation has occurred. Once reconstituted, if the solution is cloudy or contains floating particles, discard it immediately. Do not inject degraded peptides.

Administer TB-500 during the loading phase (2–2.5 mg twice weekly for two weeks) to stimulate fibroblast migration into chronic scar tissue, followed by BPC-157 at 300–400 mcg twice daily to promote vascular ingrowth. Chronic injuries (>8 weeks post-onset) have transitioned from the proliferative phase to the remodeling phase, where collagen turnover slows and scar tissue has already formed. Peptides can still modulate this tissue, but the response magnitude decreases compared to acute-phase intervention. Combining peptide therapy with eccentric loading exercises (e.g., reverse wrist curls for tennis elbow) mechanically disrupts disorganized scar tissue and creates a micro-injury environment where peptides can signal organized repair.

Discard the vial immediately. Cloudiness indicates incomplete dissolution, peptide aggregation, or bacterial contamination. Properly reconstituted BPC-157, TB-500, and GHK-Cu should be crystal-clear solutions with no visible particles or precipitate. Aggregated peptides lose bioactivity because the three-dimensional protein structure required for receptor binding is disrupted. Injecting aggregated peptide doesn't just reduce efficacy, it can trigger immune responses against the denatured protein fragments. Reconstitute peptides using bacteriostatic water (0.9% benzyl alcohol) at 2–4°C (refrigerator temperature), inject the water slowly down the vial wall rather than directly onto the lyophilized powder, and allow 5–10 minutes for complete dissolution without shaking or vortexing.

Start BPC-157 within 72 hours of injury. The angiogenesis window. When new blood vessel formation is most responsive to VEGF signaling. Peaks 48–96 hours post-injury. Delaying beyond this reduces the peptide's structural repair benefit, leaving you with only the anti-inflammatory effect (which corticosteroids provide more potently). Dosing: 250–350 mcg subcutaneously once daily for 14–21 days, then reassess.

Reduce injection frequency by using sustained-release formulations or switch to suprachoroidal delivery. A 2020 study in Translational Vision Science & Technology found that suprachoroidal microinjection of PLGA-BDNF particles avoided lens trauma entirely and maintained therapeutic vitreal levels for 8 weeks. The learning curve is steeper than intravitreal technique. Incorrect needle angle punctures the retina. But long-term studies benefit from eliminating weekly trauma.

NSAIDs (ibuprofen, naproxen) block COX enzymes, which reduces prostaglandin synthesis and dampens the inflammatory signals that guide early-stage healing. Long-term NSAID use (beyond 7–10 days) is associated with delayed bone healing and increased non-union rates in fracture studies. BPC-157 and TB-500 work through independent pathways (FAK-paxillin and actin regulation) that don't rely on COX activity, so direct interference is unlikely. The concern is that NSAIDs suppress the baseline inflammatory environment peptides are meant to modulate. Not amplify or suppress, but guide toward resolution.

Gabapentinoids work by blocking calcium channels to reduce signal transmission. They don't repair damaged nerves. If your neuropathy stems from structural damage (chemotherapy-induced neuropathy, diabetic neuropathy, post-herpetic neuralgia), peptides that promote nerve regeneration operate through a completely different mechanism. The timeline differs: gabapentin may reduce pain within days, while peptides targeting axonal regrowth require weeks to months before measurable changes in nerve conduction appear. Peptide therapy is not a faster analgesic. It's a structural intervention with delayed onset.

That symptom profile suggests autonomic nervous system dysregulation rather than pure GABAergic deficiency. Selank would still be the first-line research compound because it normalizes sympathetic-parasympathetic balance alongside its GABA effects. Animal studies show Selank reduces heart rate variability in stressed subjects. Normalizing the exaggerated fight-or-flight response that produces physical anxiety symptoms. Expect physical symptoms to respond within 7–10 days if the mechanism is GABAergic; if no change after 14 days, the driver is likely inflammatory or HPA-related rather than neurotransmitter-based.